Key facts
- Orchidia Pharmaceutical Industries’s last known valuation is $85.2M (Nov 2017).
- Notable investors include European Bank for Reconstruction and Development, Proparco, Belgian Investment Company for Developing Countries, Egyptian-American Enterprise Fund, Lorax Capital Partners.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Orchidia Pharmaceutical Industries
- ·The full record, as it builds
Funding rounds
No funding rounds for Orchidia Pharmaceutical Industries are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Orchidia Pharmaceutical Industries
Manufacturer of pharmaceutical ophthalmic, cosmeceutical, and food supplement products intended to support ocular health and overall wellness. The company offers subconjunctival and intraocular injection solutions, anti-inflammatory eye drops, lens care products, and eye vitamins, enabling healthcare providers and patients to access affordable and consistently available eye care treatments.
- Sector
- Healthcare
- HQ
- Cairo, Egypt
- Founded
- 1993
- Employees
- 554
- Website
- orchidiapharma.com/
- Ownership
- Privately Held (backing)
Orchidia Pharmaceutical Industries doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Orchidia Pharmaceutical Industries shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Orchidia Pharmaceutical Industries in its N-PORT filings yet. We sweep new filings monthly.